PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulton, Ben, Short, Susan C., James, Allan, Nowicki, Stefan, McBain, Catherine, Jefferies, Sarah, Kelly, Caroline, Stobo, Jon, Morris, Anna, Williamson, Aoife, Chalmers, Anthony J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862667/
https://www.ncbi.nlm.nih.gov/pubmed/29594237
http://dx.doi.org/10.1016/j.ctro.2017.11.003
_version_ 1783308271380070400
author Fulton, Ben
Short, Susan C.
James, Allan
Nowicki, Stefan
McBain, Catherine
Jefferies, Sarah
Kelly, Caroline
Stobo, Jon
Morris, Anna
Williamson, Aoife
Chalmers, Anthony J.
author_facet Fulton, Ben
Short, Susan C.
James, Allan
Nowicki, Stefan
McBain, Catherine
Jefferies, Sarah
Kelly, Caroline
Stobo, Jon
Morris, Anna
Williamson, Aoife
Chalmers, Anthony J.
author_sort Fulton, Ben
collection PubMed
description Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.
format Online
Article
Text
id pubmed-5862667
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-58626672018-03-28 PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status Fulton, Ben Short, Susan C. James, Allan Nowicki, Stefan McBain, Catherine Jefferies, Sarah Kelly, Caroline Stobo, Jon Morris, Anna Williamson, Aoife Chalmers, Anthony J. Clin Transl Radiat Oncol Article Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules. Elsevier 2017-11-21 /pmc/articles/PMC5862667/ /pubmed/29594237 http://dx.doi.org/10.1016/j.ctro.2017.11.003 Text en © 2017 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fulton, Ben
Short, Susan C.
James, Allan
Nowicki, Stefan
McBain, Catherine
Jefferies, Sarah
Kelly, Caroline
Stobo, Jon
Morris, Anna
Williamson, Aoife
Chalmers, Anthony J.
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_full PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_fullStr PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_full_unstemmed PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_short PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_sort paradigm-2: two parallel phase i studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by mgmt status
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862667/
https://www.ncbi.nlm.nih.gov/pubmed/29594237
http://dx.doi.org/10.1016/j.ctro.2017.11.003
work_keys_str_mv AT fultonben paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT shortsusanc paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT jamesallan paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT nowickistefan paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT mcbaincatherine paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT jefferiessarah paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT kellycaroline paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT stobojon paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT morrisanna paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT williamsonaoife paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT chalmersanthonyj paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus

Ejemplares similares